JP2025506821A5 - - Google Patents
Info
- Publication number
- JP2025506821A5 JP2025506821A5 JP2024550241A JP2024550241A JP2025506821A5 JP 2025506821 A5 JP2025506821 A5 JP 2025506821A5 JP 2024550241 A JP2024550241 A JP 2024550241A JP 2024550241 A JP2024550241 A JP 2024550241A JP 2025506821 A5 JP2025506821 A5 JP 2025506821A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- receptor
- glp
- agonists
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263313363P | 2022-02-24 | 2022-02-24 | |
| US63/313,363 | 2022-02-24 | ||
| PCT/IL2023/050192 WO2023161934A1 (en) | 2022-02-24 | 2023-02-23 | Formulations comprising acid-neutralizing polymer for oral administration of active agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025506821A JP2025506821A (ja) | 2025-03-13 |
| JP2025506821A5 true JP2025506821A5 (cg-RX-API-DMAC7.html) | 2026-01-07 |
Family
ID=87765060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024550241A Pending JP2025506821A (ja) | 2022-02-24 | 2023-02-23 | 活性薬剤の経口投与用の酸中和ポリマーを含む製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250186558A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4482507A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025506821A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240152915A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119053335A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023226618A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3251862A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL315198A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024010387A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023161934A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025046589A1 (en) * | 2023-08-30 | 2025-03-06 | Entera Bio Ltd. | Formulations comprising a combination of acid-neutralizing polymeric and non-polymeric substances for oral administration of active agents |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5175553B2 (ja) * | 2005-02-01 | 2013-04-03 | エミスフェアー・テクノロジーズ・インク | 胃内滞留および制御放出型送達系 |
| WO2008070543A1 (en) * | 2006-12-01 | 2008-06-12 | Emisphere Technologies Inc. | Improved acyclovir formulations |
| US20090124639A1 (en) * | 2007-11-06 | 2009-05-14 | Emisphere Technologies Inc. | valacyclovir formulations |
| WO2016128972A1 (en) * | 2015-02-09 | 2016-08-18 | Entera Bio Ltd. | Formulations for oral administration of active agents with controlled absorption profile |
| MX2019001850A (es) * | 2016-08-17 | 2019-05-15 | Entera Bio Ltd | Formulaciones para administracion oral de principios activos. |
| WO2018121702A1 (zh) * | 2016-12-30 | 2018-07-05 | 江苏恒瑞医药股份有限公司 | 一种glp-1类似物的药物组合物及其制备方法 |
| CN112587496A (zh) * | 2020-12-16 | 2021-04-02 | 江苏海洋大学 | 一种艾塞那肽肠溶胶囊及其制备方法 |
-
2023
- 2023-02-23 KR KR1020247031757A patent/KR20240152915A/ko active Pending
- 2023-02-23 EP EP23759464.3A patent/EP4482507A4/en active Pending
- 2023-02-23 JP JP2024550241A patent/JP2025506821A/ja active Pending
- 2023-02-23 CA CA3251862A patent/CA3251862A1/en active Pending
- 2023-02-23 IL IL315198A patent/IL315198A/en unknown
- 2023-02-23 AU AU2023226618A patent/AU2023226618A1/en active Pending
- 2023-02-23 US US18/841,377 patent/US20250186558A1/en active Pending
- 2023-02-23 CN CN202380034392.0A patent/CN119053335A/zh active Pending
- 2023-02-23 MX MX2024010387A patent/MX2024010387A/es unknown
- 2023-02-23 WO PCT/IL2023/050192 patent/WO2023161934A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12257229B2 (en) | Peptide pharmaceuticals for treatment of NASH and other disorders | |
| JP5749879B2 (ja) | ペプチドyyおよびペプチドyyアゴニストの送達用組成物 | |
| RU2492183C2 (ru) | Пептид, фармацевтическая композиция (варианты) и лекарственное средство на его основе, способ лечения и/или предупреждения диабета или заболеваний, сопутствующих ожирению, способ уменьшения аппетита, уменьшения потребления пищи, уменьшения потребления калорий, уменьшения массы тела и увеличения расхода энергии | |
| JP4898078B2 (ja) | 薬理学的活性剤の経口的送達のための医薬組成物 | |
| US20050009748A1 (en) | Compositions for delivering peptide YY and PYY agonists | |
| JP6118107B2 (ja) | Raの処置のためのカルシトニンの使用 | |
| WO2023066293A1 (en) | Oral delivery of therapeutic agents | |
| CN1809377B (zh) | 包含微粉化形式的传送剂的口服给药药物组合物 | |
| ES2393324T3 (es) | Compuestos y composiciones para administrar principios activos | |
| JP2024501467A (ja) | 新規化合物 | |
| CN106255701A (zh) | 可从前胰高血糖素原衍生出的肽激素类似物 | |
| JP2025525218A (ja) | インクレチンアナログおよびその使用 | |
| CN118019522A (zh) | 包含大的生理活性物质和赋形剂的药物组合物 | |
| EP4638481A1 (en) | Glp1/gip/npy2 receptor triple agonists | |
| CN118108832A (zh) | 一种长效的类似胰淀素的多肽衍生物及其制备方法和用途 | |
| JP2022536761A (ja) | 新規ペプチドホルモン類縁体 | |
| JP7279061B2 (ja) | グルカゴン様ペプチド | |
| EP0462071A1 (en) | Pharmaceutical resorption-improved somatostatin compositions, their preparation and use | |
| Wang et al. | Peptide and peptide-based drugs | |
| US20220143150A1 (en) | Glucagon-like peptide-1 (glp-1) agonist analog, process of preparation and uses thereof | |
| EP4631514A1 (en) | Oral polypeptide composition and use thereof | |
| WO2024012589A1 (zh) | 一种多肽组合物、药物、药物组合物及其应用 | |
| JP5264725B2 (ja) | ペプチド性薬物の粘膜吸収促進剤を含有する粘膜投与用組成物、及びその投与方法 | |
| JPH069424A (ja) | 経粘膜用製剤 | |
| US20260077020A1 (en) | Oral peptide pharmaceutical composition that facilitates enhanced oral absorption |